RenovoRx, Inc. (RNXT) Form 10-Q — Aug 13, 2026
RenovoRx posted record Q2 2026 revenue of $909,000 from RenovoCath device sales, up approximately 115% year-over-year and 61% sequentially, driven by expansion to 21 active commercial cancer centers and repeat ordering, with the total commercial funnel growing to 63 centers. On August 7, 2026, the company notified TIGeR-PaC trial investigators that patient enrollment is closing in its Phase III trial of intra-arterial gemcitabine for locally advanced pancreatic cancer. Trial completion is expected in the first half of 2027 after 86 events (78 observed as of August 11, 2026), with top-line data expected in the second half of 2027.
Key figures
- Revenue
- 909000
- Revenue Yoy
- 115% (Q2 2026 vs Q2 2025)
- Cash Position
- 9479000
- Shares Outstanding
- 45129508
- Q2 2026 rnd
- 1200000
- Q2 2026 sgna
- 2915000
- Total assets
- 11472000
- H1 2025 revenue
- 619000
- H1 2026 revenue
- 1472000
- Accumulated deficit
- 67819000
- Options outstanding
- 6449232
- Stockholders equity
- 8979000
- Q2 2026 gross profit
- 766000
- Warrants outstanding
- 28554994
- Tigrepac events observed
- 78 of 86 required as of August 11, 2026
- Q2 customer concentration
- Customers A, B, C accounted for 20.0%, 16.8% and 15.2% of Q2 revenue
- Tam standalone renovocath
- 400000000
- Potentially dilutive shares
- 35032804
- Shelf registration capacity
- 50000000
- Year end active center target
- 36 by year-end 2026
- Capital raised since inception
- 81400000
- Tam platform peak annual sales
- more than $1 billion
- Total commercial funnel centers
- 63
- Active commercial cancer centers
- 21
- Medical murray purchase commitment
- 1500000
- March 2026 private placement gross proceeds
- 10000000
Price after filing
Close on the filing date to close N calendar days later (from $1.15). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.